Department of Radiology, St-Eloi University Hospital, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
Department of Nuclear Medicine, Centre de Lutte Contre le Cancer Eugène Marquis, 35000, Rennes, France.
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1599-1607. doi: 10.1007/s00270-022-03072-8. Epub 2022 Feb 11.
The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly used staging system for hepatocellular carcinoma (HCC) in Western countries. BCLC aims to categorize patients into five stages with different prognoses and to allocate treatment according to these stages based on the best possible contemporary evidence. Transarterial radioembolization (TARE) has recently entered at the left of the BCLC algorithm (i.e., BCLC 0-A), mainly because of negative phase III trials in BCLC C stage. TARE has shown a steady increase in nationwide studies over the past 20 years and has even been adopted in some tertiary centers as the primary HCC treatment across all BCLC stages. We aimed to review the history of TARE in HCC, starting from advanced HCC and gradually expanding to earlier stages at the left of the BCLC system.
巴塞罗那临床肝癌（BCLC）分期系统是西方国家最常用于肝细胞癌（HCC）的分期系统。BCLC 的目的是根据最佳的现代循证医学证据，将患者分为五个不同预后的阶段，并根据这些阶段分配治疗。经肝动脉放射性栓塞术（TARE）最近已进入 BCLC 算法的左侧（即 BCLC 0-A），主要是因为在 BCLC C 期的三期临床试验为阴性。在过去的 20 年中，TARE 在全国性研究中稳步增加，甚至在一些三级中心被采纳为所有 BCLC 阶段的原发性 HCC 治疗的首选。我们旨在回顾 HCC 中 TARE 的历史，从晚期 HCC 开始，逐渐扩展到 BCLC 系统左侧的早期阶段。
